A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Dupilumab (Primary) ; SAR 440340 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 21 Nov 2019 Planned End Date changed from 31 Aug 2020 to 5 Jan 2021, as reported by ClinicalTrials.gov.
- 21 Nov 2019 Planned primary completion date changed from 30 Mar 2020 to 3 Aug 2020, as reported by ClinicalTrials.gov.
- 12 Jun 2019 Planned End Date changed from 28 Aug 2020 to 31 Aug 2020.